Full metadata record
DC FieldValueLanguage
dc.contributor.authorZhu, Jing-
dc.contributor.authorZhou, Rui-
dc.contributor.authorXiao, Heng-
dc.date.accessioned2020-10-06T13:04:19Z-
dc.date.available2020-10-06T13:04:19Z-
dc.date.issued2020-02-28-
dc.identifier.citationhttps://doi.org/10.17179/excli2019-1964de
dc.identifier.issn1611-2156-
dc.identifier.urihttp://hdl.handle.net/2003/39763-
dc.identifier.urihttp://dx.doi.org/10.17877/DE290R-21655-
dc.description.abstractEpidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are currently recommended by international guidelines as first-line treatment in patients with advanced EGFR-mutant non-small-cell lung cancer. With the availability of drugs, more and more patients choose EGFR-TKI treatment. However, pharmaceutical drugs used in clinical practice have side effects, such as diarrhea, paronychia, and hepatotoxicity. Mental or conscious disturbance has never been reported before. In our clinical center, we found that several patients with advanced lung adenocarcinoma developed a mental disorder or conscious disturbance after EGFR-TKI treatment. This situation has not previously been reported. We conducted a retrospective study of patients with advanced lung adenocarcinoma treated with EGFR-TKI who showed a mental disorder or conscious disturbance. We reported five cases of lung adenocarcinoma who developed a mental disorder or conscious disturbance after treatment with EGFR-TKI. The main clinical symptoms of these patients were sluggishness, memory deterioration, cognitive disorder, and even hallucination. Brain magnetic resonance imaging showed increased ischemic foci and lacunar infarction, worse encephalatrophy, and demyelination after EGFR-TKI therapy. These psychiatric symptoms did not improve but worsened after taking antipsychotic drugs, suggesting that they were irreversible. The neuropsychiatric symptoms in EGFR-TKI treatment must be considered, and the underlying reason warrants further study.en
dc.language.isoen-
dc.publisherIfADo - Leibniz Research Centre for Working Environment and Human Factors, Dortmundde
dc.relation.ispartofseriesEXCLI Journal;Vol. 19. 2020, 230-238-
dc.subjectAdvanced lung adenocarcinomaen
dc.subjectConscious disturbanceen
dc.subjectEpidermal growth factor receptor-tyrosine kinase inhibitoren
dc.subjectMental disorderen
dc.subject.ddc610-
dc.titleMental disorder or conscious disturbance in epidermal growth factor receptor-tyrosine kinase inhibitor treatment of advanced lung adenocarcinomaen
dc.typeText-
dc.type.publicationtypearticle-
dcterms.accessRightsopen access-
eldorado.dnb.zdberstkatid2132560-1-
eldorado.secondarypublicationtrue-
Appears in Collections:Case Reports 2020

Files in This Item:
File Description SizeFormat 
Xiao_28022020_proof.pdfDNB1.23 MBAdobe PDFView/Open


This item is protected by original copyright



All resources in the repository are protected by copyright.